Outlook Therapeutics, Inc.
Ticker: 1649989
values in millions
| Period | Q3 FY25 |
|---|---|
| INCOME | |
| Revenue | 1.51 |
| Total Income | 1.51 |
| EXPENSES | |
| Expenditure | 17.25 |
| PROFIT | |
| PBT | -20.15 |
| Net Profit | -20.15 |
| KEY METRICS | |
| OPM % | -100.00% |
| NPM % | -100.00% |
| EPS | -0.55 |
Corporate Events
Board MeetingOTLK
20261Sep
Board Meeting
Kevin Lundquist appointed Chief Financial Officer, replacing…
SEC Filing ↗ Board MeetingOTLK
202614Aug
Board Meeting
Outlook Therapeutics to host corporate update conference cal…
SEC Filing ↗ Board MeetingOTLK
202621Jul
Board Meeting
Compensation Committee approved stock option grants and cash…
SEC Filing ↗ Board MeetingOTLK
202616Jul
Board Meeting
Stockholders to vote on the approval of common stock issuanc…
SEC Filing ↗